Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02668991 · ClinicalTrials.gov registry record
Study to Assess the Janssen Autism Knowledge Engine in Participants With Autism Spectrum Disorder and in a Normally Developing Cohort
A clinical trial of Autism Spectrum Disorder, sponsored by Janssen Research & Development.
- Completed
- Registry status
- 186
- Enrollment target
- 9
- Study locations
NCT02668991 is a study of Autism Spectrum Disorder that has completed, run by Janssen Research & Development. The registered enrollment target is 186 participants, above the 134-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (39% higher). The trial reports 9 study locations across 9 states.
The verdict
NCT02668991, a study of Autism Spectrum Disorder, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- 186 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this study is to evaluate the utility of and to clinically validate the Autism Behavior Inventory (ABI) in measuring clinical symptoms of Autism Spectrum Disorder (ASD) compared with other gold standard measures.
Conditions Studied
Study Locations (9)
Arizona
- - Phoenix
California
- - San Francisco
Connecticut
- - New Haven
Massachusetts
- - Worcester
New Jersey
- - Toms River
New York
- - Orangeburg
North Carolina
- - Durham
Pennsylvania
- - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 186 participants |
| Start Date | 2015-07 |
| Est. Completion | 2016-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02668991
The ClinicalTrials.gov registry entry for NCT02668991 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 186 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 134-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (39% higher). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Autism Spectrum Disorder appearing as the primary indexed condition, and to 0 interventions.
NCT02668991 reports 9 study locations spanning 9 distinct geographic areas - top geographies include Arizona, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT02668991 about?
NCT02668991 is a clinical study titled "Study to Assess the Janssen Autism Knowledge Engine in Participants With Autism Spectrum Disorder and in a Normally Developing Cohort". The purpose of this study is to evaluate the utility of and to clinically validate the Autism Behavior Inventory (ABI) in measuring clinical symptoms of Autism Spectrum Disorder (ASD) compared with other gold standard measures.
What is the current status of trial NCT02668991?
This trial is currently completed. The enrollment target is 186 participants. The study started on 2015-07. Estimated completion is 2016-10.
What conditions does trial NCT02668991 study?
This clinical trial studies the following conditions: Autism Spectrum Disorder.
Who is sponsoring clinical trial NCT02668991?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02668991 being conducted?
This trial has 9 study locations across Arizona, California, Connecticut, Massachusetts, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autism Spectrum Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of an 8-Week Pickleball Program for Adults With Autism: A Feasibility Trial With a Delayed-Control Design
RECRUITING · Early Phase 1
-
Cannabidiol (CBD) in Adults With ASD
RECRUITING · Phase 1
-
COMPASS Across Settings (CAST) for Improving Transition Outcomes for Students With ASD
RECRUITING · NA
-
Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder
RECRUITING · Phase 2
-
Emergent Multi-Class Imitation Training
RECRUITING · NA
-
Physical Activity and Community EmPOWERment Project
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.